Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders
Background: Hepatitis C virus (HCV)-infected patients who achieved sustained virologic response (SVR) may still develop hepatocellular carcinoma (HCC). The characteristic of HCC and the prognosis between SVR and non-SVR patients were not well known. Methods: Among 1884 HCV-infected patients who were...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Journal of the Formosan Medical Association |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664618302742 |
| _version_ | 1828973686691987456 |
|---|---|
| author | Fai-Meng Sou Cheng-Kun Wu Kuo-Chin Chang Sheng-Nan Lu Jing-Houng Wang Chao-Hung Hung Chien-Hung Chen Kwong-Ming Kee Yi-Hao Yen Ming-Tsung Lin Ming-Chao Tsai Tsung-Hui Hu |
| author_facet | Fai-Meng Sou Cheng-Kun Wu Kuo-Chin Chang Sheng-Nan Lu Jing-Houng Wang Chao-Hung Hung Chien-Hung Chen Kwong-Ming Kee Yi-Hao Yen Ming-Tsung Lin Ming-Chao Tsai Tsung-Hui Hu |
| author_sort | Fai-Meng Sou |
| collection | DOAJ |
| description | Background: Hepatitis C virus (HCV)-infected patients who achieved sustained virologic response (SVR) may still develop hepatocellular carcinoma (HCC). The characteristic of HCC and the prognosis between SVR and non-SVR patients were not well known. Methods: Among 1884 HCV-infected patients who were treated with pegylated IFN plus ribavirin therapies, 122 patients developed HCC during follow-up were enrolled in this study. Laboratory data were collected before and at least 1 year after IFN-based therapy, as well as the latest follow-up. Results: Both SVR and non-SVR patients had similar risk factors to develop HCC, but with a little difference. Liver cirrhosis plays a key role in HCC occurrence in both groups. Among the patients who developed HCC, non-SVR patients had significantly higher total bilirubin, higher FIB-4, lower pre-treatment platelet count, higher pre-treatment AFP levels and higher proportion of cirrhosis than SVR patients before occurrence of HCC. After curative treatment, SVR patients had lower recurrence and longer overall survival than non-SVR patients by Kaplan–Meier analysis. Multivariate analysis revealed that APRI ≥0.7 was the independent risk factor for HCC recurrence; and AFP ≥20 ng/ml post IFN therapy, as well as HCC recurrence were the independent risk factors of mortality. Conclusion: Liver cirrhosis plays a key role in HCC occurrence after antiviral therapies. SVR patients may have lower HCC recurrence and longer survival rates than non-SVR patients. Only APRI was associated with HCC recurrence; and post-IFN AFP and HCC recurrence were predictive of subsequent mortality independently. Keywords: Hepatitis C virus, Hepatocellular carcinoma, Mortality, Recurrence, Antiviral therapy |
| first_indexed | 2024-12-14T13:49:36Z |
| format | Article |
| id | doaj.art-96d7fbf0375340c3853a8e33004d3bd4 |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-12-14T13:49:36Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-96d7fbf0375340c3853a8e33004d3bd42022-12-21T22:59:09ZengElsevierJournal of the Formosan Medical Association0929-66462019-01-011181504513Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained respondersFai-Meng Sou0Cheng-Kun Wu1Kuo-Chin Chang2Sheng-Nan Lu3Jing-Houng Wang4Chao-Hung Hung5Chien-Hung Chen6Kwong-Ming Kee7Yi-Hao Yen8Ming-Tsung Lin9Ming-Chao Tsai10Tsung-Hui Hu11Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanCorresponding author. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Kaohsiung, Taiwan. Fax: +886 7 732 2402.; Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanBackground: Hepatitis C virus (HCV)-infected patients who achieved sustained virologic response (SVR) may still develop hepatocellular carcinoma (HCC). The characteristic of HCC and the prognosis between SVR and non-SVR patients were not well known. Methods: Among 1884 HCV-infected patients who were treated with pegylated IFN plus ribavirin therapies, 122 patients developed HCC during follow-up were enrolled in this study. Laboratory data were collected before and at least 1 year after IFN-based therapy, as well as the latest follow-up. Results: Both SVR and non-SVR patients had similar risk factors to develop HCC, but with a little difference. Liver cirrhosis plays a key role in HCC occurrence in both groups. Among the patients who developed HCC, non-SVR patients had significantly higher total bilirubin, higher FIB-4, lower pre-treatment platelet count, higher pre-treatment AFP levels and higher proportion of cirrhosis than SVR patients before occurrence of HCC. After curative treatment, SVR patients had lower recurrence and longer overall survival than non-SVR patients by Kaplan–Meier analysis. Multivariate analysis revealed that APRI ≥0.7 was the independent risk factor for HCC recurrence; and AFP ≥20 ng/ml post IFN therapy, as well as HCC recurrence were the independent risk factors of mortality. Conclusion: Liver cirrhosis plays a key role in HCC occurrence after antiviral therapies. SVR patients may have lower HCC recurrence and longer survival rates than non-SVR patients. Only APRI was associated with HCC recurrence; and post-IFN AFP and HCC recurrence were predictive of subsequent mortality independently. Keywords: Hepatitis C virus, Hepatocellular carcinoma, Mortality, Recurrence, Antiviral therapyhttp://www.sciencedirect.com/science/article/pii/S0929664618302742 |
| spellingShingle | Fai-Meng Sou Cheng-Kun Wu Kuo-Chin Chang Sheng-Nan Lu Jing-Houng Wang Chao-Hung Hung Chien-Hung Chen Kwong-Ming Kee Yi-Hao Yen Ming-Tsung Lin Ming-Chao Tsai Tsung-Hui Hu Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders Journal of the Formosan Medical Association |
| title | Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders |
| title_full | Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders |
| title_fullStr | Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders |
| title_full_unstemmed | Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders |
| title_short | Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders |
| title_sort | clinical characteristics and prognosis of hcc occurrence after antiviral therapy for hcv patients between sustained and non sustained responders |
| url | http://www.sciencedirect.com/science/article/pii/S0929664618302742 |
| work_keys_str_mv | AT faimengsou clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT chengkunwu clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT kuochinchang clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT shengnanlu clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT jinghoungwang clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT chaohunghung clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT chienhungchen clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT kwongmingkee clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT yihaoyen clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT mingtsunglin clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT mingchaotsai clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders AT tsunghuihu clinicalcharacteristicsandprognosisofhccoccurrenceafterantiviraltherapyforhcvpatientsbetweensustainedandnonsustainedresponders |